Abstracts tagged "Castleman’s disease and IgG4 Related Disease"

Abstract Number: 1179 • 2017 ACR/ARHP Annual Meeting
A Multi-Organ Inflammatory Condition with Features of Idiopathic Multicentric Castleman’s Disease and IgG4-Related Disease: An Unrecognized Mimicker of IgG4-RD
Zachary S. Wallace¹, Yasuharu Sato², Kazuichi Okazaki³, Judith Ferry⁴, Hisanori Umehara⁵, Aliyah Sohani⁶, Mitsuhiro Kawano⁷, Nancy Harris⁶, Yoshiya Tanaka⁸, Cory A. Perugino⁹, Satoshi Kubo¹⁰, James Stone⁴, Robert Colvin⁴, Tsutomu Chiba¹¹, John H. Stone¹² and Yoh Zen¹³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Pathology, Okayama University Graduate School of Medicine, Okayama, Japan, ³Department of Gastroenterology and Hepatology, Kansai Medical University, Osaka, Japan, ⁴Department of Pathology, Massachusetts General Hospital, Boston, MA, ⁵Kyoto University, Kyoto, Japan, ⁶Massachusetts General Hospital, Boston, MA, ⁷Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan, ⁹Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ¹⁰The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹¹Department of Gastroenterology and Hepatology, Kyoto University, Kyoto, MA, ¹²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹³Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Some of clinical features of the plasma cell type of human herpesvirus-8-negative multicentric Castleman’s disease (idiopathic MCD or iMCD) are similar to those of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].